SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-029551
Filing Date
2021-11-22
Accepted
2021-11-22 16:00:44
Documents
53
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 586560
2 ex31-1.htm EX-31.1 13857
3 ex31-2.htm EX-31.2 13804
4 ex32.htm EX-32 11290
  Complete submission text file 0001493152-21-029551.txt   3748978

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE bcyp-20210930.xsd EX-101.SCH 32243
6 XBRL CALCULATION FILE bcyp-20210930_cal.xml EX-101.CAL 33845
7 XBRL DEFINITION FILE bcyp-20210930_def.xml EX-101.DEF 154258
8 XBRL LABEL FILE bcyp-20210930_lab.xml EX-101.LAB 239054
9 XBRL PRESENTATION FILE bcyp-20210930_pre.xml EX-101.PRE 205739
10 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 580239
Mailing Address 300 W. 41ST STREET SUITE 202 MIAMI BEACH FL 33140
Business Address 300 W. 41ST STREET SUITE 202 MIAMI BEACH FL 33140 (305) 204-3338
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39871 | Film No.: 211432483
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences